{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-048426","form_type":"8-K","ticker":"AVIR","cik":"0001593899","company_name":"Atea Pharmaceuticals, Inc.","filed_at":"2025-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.110070+00:00","generated_at":"2026-05-25T05:59:55.514379+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Atea reports Q4/FY2024 results; cash at $454.7M; HCV Phase 3 starts April 2025","bullets":["Net loss per share Q4 2024 improved to ($0.40) from ($0.47); full year net loss per share ($2.00) vs ($1.63).","Cash, cash equivalents and marketable securities $454.7M at Dec 31, 2024 vs $578.1M year earlier.","Successful End-of-Phase 2 FDA meeting for HCV regimen bemnifosbuvir/ruzasvir; Phase 3 enrollment expected April 2025.","Reduced workforce by 25% in Q1 2025 to achieve ~$15M in cost savings through 2027.","Engaged Evercore for strategic partnerships for HCV Phase 3 program; appointed Arthur S. Kirsch to board."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-048426","json":"https://secwatch.observer/filing/0001193125-25-048426.json","markdown":"https://secwatch.observer/filing/0001193125-25-048426.md","text":"https://secwatch.observer/filing/0001193125-25-048426.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1593899/000119312525048426/0001193125-25-048426-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1593899/000119312525048426/d925111d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T05:59:55.514379+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}